Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods for diagnosing and treating cerebrovascular events based on NR2 peptides

a technology of cerebrovascular events and peptides, applied in the direction of nervous disorders, drug compositions, instruments, etc., can solve the problems of insufficient guidance regarding significant future risk of stroke and associated morbidity and mortality for patients with symptoms suggestive of tia, and inability to definitively guide the early evaluation and disposition of such patients. , to achieve the effect of enhancing the ability of physicians to identify, enhancing the accuracy of diagnoses and subsequen

Inactive Publication Date: 2006-12-14
CIS BIOTECH
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019] It is another object of the present invention to detect bound or total NR2 peptide to accurately diagnose chronic TIA and stroke to the exclusion of stroke-like disorders in conjunction with NIHSS evaluations and neuroimaging.
[0029] Once again, these correlations can be extensively used for the choice of emergency treatment such as anti-platelet or neuroprotective therapy in a short time frame. The biomarker profile provides real time evidence of a cerebrovascular accident, and the reduction in concentration of circulating total NR2 peptide correlates well with positive effect of chosen therapy. The methods of the present invention also can be employed in a primary care setting, when evaluating a cerebrovascular accident or TIA, and in identifying patients who are at subsequently high risk in the near term of TIA or completed stroke. In addition, based upon results showing an increased risk of suffering TIA or stroke, prevention therapy can be administered, and the effectiveness of the therapy monitored using the methods of the present invention.

Problems solved by technology

Transient ischemic attack portends significant future risk of stroke and its associated morbidity and mortality.
Despite the significant impact of this disease process there is still no definitive guidance concerning the early evaluation and disposition of such patients presenting to the Emergency Department.
It appears that a certain subset of patients presenting to the Emergency Department with symptoms suggestive of TIA are at substantial risk in the short term of suffering a completed stroke.
Such high-risk patients are unlikely to receive a complete diagnostic evaluation and implementation of an appropriate therapeutic regimen (medical or surgical) as an outpatient in less than 48 hours.
Transient ischemic attack is a clinical diagnosis and inter-observer reliability concerning the diagnosis is often poor.
Although numerous, none of these technologies is able to predict stroke or directly diagnose cerebrovascular abnormalities or TIA / stroke.
However, MRI scans require a longer time window for imaging.
Currently MRI does not readily distinguish hemorrhagic stroke prior to 6 hrs and is thus not considered a primary diagnostic modality.
Although effective, each of these imaging techniques is limited by high capital costs and service requirements.
There are no blood tests currently available in the Emergency Department that answer these unmet diagnostic needs by diagnosing acute cerebrovascular accidents, TIA, and ischemic stroke and ruling out stroke mimics.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for diagnosing and treating cerebrovascular events based on NR2 peptides
  • Methods for diagnosing and treating cerebrovascular events based on NR2 peptides
  • Methods for diagnosing and treating cerebrovascular events based on NR2 peptides

Examples

Experimental program
Comparison scheme
Effect test

example 1

Patient Groups Studied

[0082] Forty one adult patients with symptoms suggestive of a possible transient ischemic attack and at high risk in the near term for a completed stroke (Table 1) were evaluated. Exclusion criteria included those patients whose symptoms resolved after treatment with glucose and were likely suffering from hypoglycemia.

[0083] During routine evaluation of the patient, the evaluating physician verified the presence or absence of five factors including: age >60, diabetes mellitus, TIA symptoms >10 minutes, weakness, speech impairment. After informed consent, blood samples were collected on the day of admission from all subjects. Patients were then followed-up approximately ninety days after presentation via telephone, personal interview, or review of medical records to assess for recurrent TIA or stroke. Stroke was defined as having occurred if a patient developed a permanent neurological deficit or new radiographic (CT or MRI) evidence of central nervous system ...

example 2

Unbound NR2 Peptide as a Marker of New Brain Lesions

[0085] Concentrations of unbound NR2 peptide in blood were obtained by direct ELISA as presented in Table 2. The distribution of unbound NR2 peptide depicted in FIG. 1 showed that patients with values of unbound NR2 peptide below 1.0 ng / ml (n=16) had no area of damage defined by CT / MRI (Table 1). The plasma of healthy persons had concentrations of unbound NR2 peptide ranging from 0.3 to 0.5 ng / ml.

TABLE 2Unbound NR2 peptide in plasma of patients studiedUnbound NR2NeuroimagingSubjectspeptide rangemodality:N(min, max), ng / mlDiagnosisCT / MRI / DWI160.3-1.0 CVA, radial &Negative or hemorrhageBell's palsies,on CTICH141.0-44.0based on NIHSS:New lesions in cortex,TIA, strokesubcortical areas,cerebellum, thalamus,lacunar

[0086] Concentrations of unbound NR2 peptide above 1.0 ng / ml were detected in plasma of patients (n=14) with new ischemic lesions located in the cortex, basal ganglia, cerebellum and thalamus defined by DWI / MRI. (Table 2). I...

example 3

Total NR2 Peptide as a Marker of Old Brain Lesions

[0087] Serum samples from 40 patients with suggestive TIA were analyzed for total NR2 peptide amounts (Table 3).

TABLE 3Amounts of total NR2 peptide in serum of patients studiedTotal NR2peptide rangeNeuroimagingSubjects(min, max),modalityNng / mlDiagnosisCT / MRI / DWI170.9-2.0CVA, radial &Negative or hemorrhageBell's palsies, ICHon CT14 2.4-24.0based on NIHSS:Old parietal infarct,TIA, strokemid white matter,lateral ventricle,MCA area

[0088] The statistical analysis of data showed that most patients had total NR2 peptide concentrations below 2.0 ng / ml (FIG. 2). Healthy persons had total NR2 peptide concentrations of 1.0-1.5 ng / ml. Neuroimaging of patients did not show abnormalities except for those with ICH. Concentrations of total NR2 peptide were >2.4 ng / ml in patients with previous history of cerebral ischemia and old infarction areas defined by MRI (Table 3). Nine patients out of 40 were clinically diagnosed as having recurrent TIA or...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, are provided based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods are optionally performed in conjunction with neurological scoring and neuroimaging, and are directed to risk assessment, prognosis, diagnosis and treatment of TIA and stroke on an emergency basis in the emergency room.

Description

RELATION TO PRIOR APPLICATIONS [0001] This application claims priority 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60 / 301,297, filed Jun. 13, 2005.FIELD OF THE INVENTION [0002] The invention relates to methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods are optionally performed in conjunction with neurological scoring and neuroimaging, and directed to risk assessment, prognosis, diagnosis and treatment of TIA and stroke on an emergency basis in the emergency room and in a primary care setting. BACKGROUND OF THE INVENTION Cerebrovascular Accident and Transient Ischemic Attack [0003] Transient ischemic attack portends significant future risk of stroke and its associated morbidity and mortality. Patients with transient ischemic attack require further evaluation to assess for any...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/53
CPCG01N33/6896G01N2800/2871G01N33/9406A61P25/00
Inventor DAMBINOVA, SVETLANA
Owner CIS BIOTECH